Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.64 USD
Change Today +0.0125 / 1.99%
Volume 57.8K
NYMX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 12:43 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

nymox pharmaceutical corp (NYMX) Snapshot

Open
$0.66
Previous Close
$0.63
Day High
$0.66
Day Low
$0.63
52 Week High
04/10/14 - $5.76
52 Week Low
12/12/14 - $0.33
Market Cap
22.4M
Average Volume 10 Days
288.2K
EPS TTM
$-0.15
Shares Outstanding
35.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NYMOX PHARMACEUTICAL CORP (NYMX)

nymox pharmaceutical corp (NYMX) Related Bloomberg News

View More Bloomberg News

nymox pharmaceutical corp (NYMX) Related Businessweek News

No Related Businessweek News Found

nymox pharmaceutical corp (NYMX) Details

Nymox Pharmaceutical Corporation, a biopharmaceutical company, is engaged in the research and development of products for the aging population. It provides NicAlert and TobacAlert products that use urine or saliva to detect use of and exposure to tobacco products, as well as AlzheimAlert, a proprietary urine assay that aid physicians in the diagnosis of Alzheimer’s disease. The company’s products under development include NX-1207, which in Phase III clinical trials for the treatment of benign prostatic hyperplasia and localized prostate cancer, as well as in human clinical trials to treat hepatocellular carcinoma; and NXC-4720, an anti-bacterial agent for the treatment of E. coli O157:H7 bacterial contamination in hamburger meat and other food and drink products, and for the treatment of urinary tract and other bacterial infections in humans. Its products under development also comprise NXB-4221 for the treatment of chronic and persistent urinary tract infections; NXB-5886 for the treatment of streptococcal infection; and NXT-1021 for the treatment of staphylococcal infection. In addition, the company is involved in the research and development of drugs at various treatments for Alzheimer's disease and other indications; drugs for the treatment of Alzheimer’s disease that targets spherons; and neural thread protein-based drugs. Further, it develops proprietary diagnostic products; has U.S. patents for using saliva to determine cholesterol levels and for a method of testing for osteoporosis; and owns patent rights to several novel biochemical indicators for Alzheimer’s disease. The company markets its tests through marketing arm and distributors in North America, Europe and Asia, as well as TobacAlert through online at tobacalert.com. Nymox Pharmaceutical Corporation has license and collaboration agreement with Recordati Ireland Ltd. for the development and commercialization of NX-1207. The company was founded in 1989 and is headquartered in Saint-Laurent, Canada.

nymox pharmaceutical corp (NYMX) Top Compensated Officers

Founder, Chairman, Chief Executive Officer, P...
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2013.

nymox pharmaceutical corp (NYMX) Key Developments

Levi & Korsinsky, LLP Notifies Investors of Class Action against Nymox Pharmaceutical Corporation and its Board of Directors

Levi & Korsinsky announced that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Nymox Pharmaceutical Corporation securities between January 31, 2011 and November 2, 2014. The complaint alleges that Nymox failed to disclose material information affecting the Phase 3 clinical trials for it's proprietary drug NX-1207 for the treatment of benign prostatic hyperplastic (BPH).

Nymox Pharmaceutical Corporation Announces Resignation of Directors

Jack Gemmell and Dr. Roger Guy have resigned from the Board of Directors of Nymox Pharmaceutical Corporation.

Robbins Arroyo LLP Files Class Action Against Nymox Pharmaceutical Corporation for Misleading Investors

Shareholder rights law firm Robbins Arroyo LLP announced that an investor of Nymox Pharmaceutical Corporation has filed a federal securities fraud class action complaint in the U.S. District Court for the Southern District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities Act of 1934 in connection with Nymox's misstatements regarding the viability of its proprietary drug NX-1207 for the treatment of benign prostatic hyperplasia. Nymox is engaged in the research and development of therapeutics and diagnostics, with an emphasis on products for the unmet needs of the aging population. According to the complaint, NX-1207 showed positive results for the treatment of BPH in Phase 1 and Phase 2 clinical trials in the United States. However, surprising the market and contrary to prior positive statements concerning Phase 3 clinical trials of NX-1207, defendants disclosed on November 2, 2014, that the Company's two Phase 3 U.S. studies of NX-1207 had to be halted because the drug failed to meets its primary endpoints for efficacy. On November 3, 2014, defendants held a conference call with analysts to explain the failure and disclosed to the market for the first time the difficulties they faced in enrolling men for the trials and keeping them enrolled for the required length of time, and the subjective nature of the measurement of the drug's success, which meant there was no scientifically acceptable basis for predicting the results in any subsequent trial using a different patient population. The market's reaction was immediate and dramatic as the price of Nymox common stock fell 82% to close at $0.93 on unprecedented trading volume of 19.6 million shares. The Company's U.S. BPH program is currently on hold pending further evaluation of data.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NYMX:US $0.64 USD +0.0125

NYMX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.08 USD +0.30
Amorfix Life Sciences Ltd C$0.04 CAD 0.00
Laboratory Corp of America Holdings $127.23 USD +0.08
OraSure Technologies Inc $6.44 USD +0.25
Quest Diagnostics Inc $77.52 USD +1.30
View Industry Companies
 

Industry Analysis

NYMX

Industry Average

Valuation NYMX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NYMOX PHARMACEUTICAL CORP, please visit www.nymox.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.